Patents by Inventor Clement Olivier

Clement Olivier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-2 analogs and peptibodies for administration before, during or after surgery
    Patent number: 11660328
    Abstract: GLP-2 analogs, such as teduglutide, and fusion proteins of GLP-2 with immunoglobulin are administered before, during or after surgery, particularly resection of the small intestine. When short bowel syndrome develops after surgical resection of the small intestine, parenteral nutrition is usually necessary to compensate for reduced absorption of water and nutrients across the small intestine. GLP-2 analogs and GLP-2 fusion proteins promote growth of small intestine, improve nutrient absorption and can reduce the need for parenteral nutrition after surgery.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: May 30, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Clark Pan, Angela Norton, Bettina Strack-Logue, Clément Olivier
  • GLP-2 ANALOGS AND PEPTIBODIES FOR ADMINISTRATION BEFORE, DURING OR AFTER SURGERY
    Publication number: 20210169986
    Abstract: GLP-2 analogs, such as teduglutide, and fusion proteins of GLP-2 with immunoglobulin are administered before, during or after surgery, particularly resection of the small intestine. When short bowel syndrome develops after surgical resection of the small intestine, parenteral nutrition is usually necessary to compensate for reduced absorption of water and nutrients across the small intestine. GLP-2 analogs and GLP-2 fusion proteins promote growth of small intestine, improve nutrient absorption and can reduce the need for parenteral nutrition after surgery.
    Type: Application
    Filed: November 5, 2018
    Publication date: June 10, 2021
    Applicant: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Clark PAN, Angela Norton, Bettina STRACK-LOGUE, Clément OLIVIER
  • Genomic markers for prediction of long-term response to 2 years of growth hormone (GH) therapy
    Patent number: 9206480
    Abstract: The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: December 8, 2015
    Assignee: ARES TRADING S.A.
    Inventors: Pascal Croteau, Benoit Destenaves, Clement Olivier, John Raelson
  • Genomic markers for prediction of long-term response to growth hormone (GH) therapy
    Patent number: 9175347
    Abstract: The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: November 3, 2015
    Assignee: MERCK SERONO SA
    Inventors: Pascal Croteau, John Raelson, Jerome Wojcik, Benoît Destenaves, Clement Olivier, Sonia Schnieper-Samec
  • GENOMIC MARKERS FOR PREDICTION OF LONG-TERM RESPONSE TO 2 YEARS OF GROWTH HORMONE (GH) THERAPY
    Publication number: 20140088012
    Abstract: The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
    Type: Application
    Filed: May 10, 2012
    Publication date: March 27, 2014
    Applicant: ARES TRADING S.A.
    Inventors: Pascal Croteau, Benoit Destenaves, Clement Olivier, John Raelson
  • GENOMIC MARKERS FOR PREDICTION OF LONG-TERM RESPONSE TO GROWTH HORMONE (GH) THERAPY
    Publication number: 20130157952
    Abstract: The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
    Type: Application
    Filed: August 31, 2011
    Publication date: June 20, 2013
    Applicant: MERCK SERONO S.A.
    Inventors: Pascal Croteau, John Raelson, Jerome Wojcik, Benoît Destenaves, Clement Olivier, Sonia Schnieper-Samec